Search bioRxiv⌕ Search

Biology subjects

Parks, B. J.

Publications and source records attributed to Parks, B. J..

2 recordsLinked to original sources

Interaction between buprenorphine and norbuprenorphine in neonatal opioid withdrawal syndrome.

Buprenorphine (BUP) is the preferred treatment for opioid use disorder during pregnancy but can cause neonatal opioid withdrawal syndrome (NOWS). Norbuprenorphine (NorBUP), an active metabolite of BUP, is implicated in BUP-associated NOWS. We hypothesized that BUP, a low-efficacy agonist of mu opioid receptors, will not antagonize NorBUP, a high-efficacy agonist of mu opioid receptors, in producing NOWS. To test this hypothesis, we treated pregnant Long-Evans rats with BUP (0, 0.01, 0.1 or 1 mg/kg/day) {+/-} NorBUP (1 mg/kg/day) from gestation day 9 until pup delivery, and tested pups for opioid dependence using our established NOWS model. We used LC-MS-MS to quantify brain concentrations of BUP, NorBUP, and their glucuronide conjugates. BUP had little effect on NorBUP-induced NOWS, with the exception of 1 mg/kg/day BUP significantly increasing NorBUP-induced NOWS by 58% in females. BUP and NorBUP brain concentrations predicted NOWS in multiple linear regression models. Interestingly, NorBUP contributed more to NOWS in females ({beta}NorBUP = 51.34, p = 0.0001) than in males ({beta}NorBUP = 19.21, P = 0.093), while BUP was similar for females ({beta}BUP = 10.62, P = 0.0017) and males ({beta}BUP = 11.38, P = 0.009). We are the first to report that NorBUP induces NOWS in the presence of BUP and that there is sexual divergence in the contribution of NorBUP to BUP-associated NOWS. These findings suggest that females are more susceptible to NorBUP-induced NOWS, and that treatment strategies that reduce prenatal NorBUP exposure may be more effective for females than males. O_LIBuprenorphine does not antagonize fetal norbuprenorphine dependence. C_LIO_LIIn females, buprenorphine and norbuprenorphine have an additive effect. C_LIO_LINorbuprenorphine contributes to NOWS in females more than in males. C_LIO_LIThe glucuronide of norbuprenorphine accumulates in fetal brain. C_LIO_LIThe glucuronide of buprenorphine does not accumulate in fetal brain. C_LI

pharmacology and toxicology↗

Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine

An active metabolite of buprenorphine (BUP), called norbuprenorphine (NorBUP), is implicated in neonatal opioid withdrawal syndrome when BUP is taken during pregnancy. Therefore, reducing or eliminating metabolism of BUP to NorBUP is a novel strategy that will likely lower total fetal exposure to opioids and thus improve offspring outcomes. Precision deuteration alters pharmacokinetics of drugs without altering pharmacodynamics. Here, we report the synthesis and testing of deuterated buprenorphine (BUP-D2). We determined opioid receptor affinities of BUP-D2 relative to BUP with radioligand competition receptor binding assays, and the potency and efficacy of BUP-D2 relative to BUP to activate G-proteins via opioid receptors with [35S]GTP{gamma}S binding assays in homogenates containing the human mu, delta, or kappa opioid receptors. The antinociceptive effects of BUP-D2 and BUP were compared using the warm-water tail withdrawal assay in rats. Blood concentration versus time profiles of BUP, BUP-D2, and NorBUP were measured in rats following intravenous BUP-D2 or BUP injection. The synthesis provided a 48% yield and the product was [≥]99% deuterated. Like BUP, BUP-D2 had sub-nanomolar affinity for opioid receptors. BUP-D2 also activated opioid receptors and induced antinociception with equal potency and efficacy as BUP. The maximum concentration and the area under the curve of NorBUP in the blood of rats that received BUP-D2 were over 19- and 10-fold lower, respectively, than in rats that received BUP. These results indicate that BUP-D2 retains key pharmacodynamic properties of BUP and resists metabolism to NorBUP and therefore holds promise as an alternative to BUP. GRAPHICAL ABSTRACT O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/520120v2_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@9ada60org.highwire.dtl.DTLVardef@76f7d0org.highwire.dtl.DTLVardef@878228org.highwire.dtl.DTLVardef@723131_HPS_FORMAT_FIGEXP M_FIG C_FIG

pharmacology and toxicology↗